Colorectal Cancer News

New Phase II Trial for Metastatic Colorectal Cancer Patients

In this study, two new anti-angiogenic agents (IMC-1121B and IMC-18F1) will be evaluated in patients receiving standard chemotherapy with a modified version of FOLFOX6. Anti-angiogenic agents shut down the tumor’s blood supply, and can be an important means to treat colorectal cancer tumors in combination with chemotherapy. Patients will randomly receive either standard therapy, or standard therapy plus one of two new agents (IMC-1121B or IMC-18F1). To learn if you are eligible for this study, call the CCA’s Clinical Trial Matching Service at (866) 278-0392 to talk to a patient navigator.

Return